Maruho Co.

Kyoto, Japan

Maruho Co.

Kyoto, Japan
SEARCH FILTERS
Time filter
Source Type

CASTRES, France--(BUSINESS WIRE)--Pierre Fabre, the 2nd largest French private Pharmaceutical group, today announced the signature of a definitive purchase agreement to acquire several assets from the biotechnology company Igenica Biotherapeutics, based in Burlingame, California, USA. The agreement includes innovative immunotherapies targeting immune checkpoints that may reverse the resistance to existing immuno therapies. The most advanced asset is currently at preclinical stage and is expected to be administered to patients in the coming 2 to 3 years. The agreement also comprises a series of early discovery targets. “This agreement is in line with recent collaborations signed by Pierre Fabre with biotechnology companies and academic laboratories in the fields of oncology and dermatology and confirms our Research & Development dynamic through external partners” said Laurent Audoly, Head of Pierre Fabre Pharmaceuticals R&D. Frédéric Duchesne, Pharmaceutical Division Chief Executive Officer at Pierre Fabre added, “Pierre Fabre’s know-how in oncology is based on more than 30 years of experience. We have two recognized research and development centers with dedicated teams that work closely together to developing medicines for patients living with cancer. This new deal reinforces our position to participate in the revolution of targeted biotherapies and reinforce our commitment to bring substantial value to patients”. Under the terms of the agreement, Pierre Fabre has acquired the full property of the assets. The financial terms of the agreement are not disclosed. “We are very pleased that Pierre Fabre will clinically develop Igenica’s most advanced immune oncology asset for patients suffering from cancer ”said Edward van der Horst, Senior Director of Igenica’s Preclinical Drug Development. About Igenica Biotherapeutics Igenica Biotherapeutics is focused on the discovery and development of antibodies in the field of immune-oncology and antibody-drug conjugates (ADCs) for the treatment of cancer. This company fully powers the ADC development spectrum from a clinically relevant approach to target and functional antibody discovery to ADC creation, accelerating development and the delivery of effective therapies to patients. Co-founded in 2009 by Robert Schreiber, Ph.D*. Igenica is led by a proven team of leaders that have demonstrated success in antibody drug discovery, clinical development and commercialization. *(Alumni endowed Professor of Pathology and Immunology, Professor of Molecular Microbiology, Washington University School of Medicine) About Pierre Fabre Pierre Fabre is a French private pharmaceuticals and dermo-cosmetics company founded in 1962 by Mr. Pierre Fabre. Its turnover reached over 2.28 billion Euros in 2016, spread over 130 countries. The company is structured around two divisions: Pharmaceuticals (prescription drugs, consumer health care) and Dermo-cosmetics (including the Europe and Asia market-leader Eau Thermale Avène brand). Pierre Fabre employs some 13,000 people worldwide and owns subsidiaries in 47 countries. In 2016, the company allocated 14% of its pharmaceuticals sales to R&D with a focus on 4 therapeutic areas: oncology, dermatology, CNS and consumer health care. Pierre Fabre Laboratories have always developed durable and valuable scientific partnerships with innovators from public research institutions (CRNS, Inserm...), faculties and universities (Ecole Polytechnique de Lausanne, Université de Saclay...), international pharmaceutical laboratories (Allergan, Abbvie, Maruho...) and biotech companies (Array BioPharma, AbCheck, Cellectar...). Through the Group’s controlling company Pierre Fabre Participations, Pierre Fabre is 86% owned by the Pierre Fabre Foundation, a recognized public-interest organization since 1999. Up to 8.2% of the remaining shares are held by the company’s employees and the remaining balance is held as treasury stock. To find out more about Pierre Fabre, please go to www.pierre-fabre.com


Patent
Maruho Co. and Mitsubishi Group | Date: 2014-02-05

Provided is an ointment which has excellent drug stability and excellent drug uniformity. The ointment, which comprises 1 to 5% by weight of 1-[2-[(4S)-4-hydroxy-1,2,3,4-tetrahydroquinolin-1-yl] -4-pyridyl] -2,3-bis(hydroxymethyl)-6,7-dimethoxynaphthalene3/2 hydrate, 3 to 7% by weight of a separation inhibitor, 15 to 50% by weight of a hydrocarbon gel, a pH controller and 0.05 to 0.4% by weight of an antioxidant, has excellent drug stability and excellent drug dispersibility. In the present ointment, polyoxyethylene (196) polyoxypropylene (67) glycol is preferred as the separation inhibitor, diisopropanolamine is preferred as the pH controller, and dibutylhydroxytoluene is preferred as the antioxidant.


Patent
Mitsubishi Group and Maruho Co. | Date: 2014-05-07

Provided is a novel pharmaceutical composition (antipruritic agent) that is useful for prophylaxis or treatment of itch in conditions such as dermal pruritus. More specifically, provided is a pharmaceutical composition (antipruritic agent) for treatment of itch comprising as an active ingredient a naphthalene compound of the following formula (I):


Patent
Maruho Co. and Maruho Hatsujyo Kogyo Co. | Date: 2015-07-08

Provided is a deformed nail corrector which enables a user to adjust magnitude of an elastic force without spending an extra cost and extra time and efforts. A deformed nail corrector 1A for correcting a deformed nail includes: a first elastic wire 2 which has one end portion thereof fixed to one edge of the deformed nail in a width direction; a second elastic wire 3 which has one end portion thereof fixed to the other edge of the deformed nail in the width direction; and a binding means 4 which binds the first and second elastic wires 2, 3 to each other and is slidable along the first and second elastic wires 2, 3 in a bound state, wherein one end portion of the first elastic wire 2 is fixed to one edge of the deformed nail in the width direction, one end portion of the second elastic wire 3 is fixed to the other edge of the deformed nail in the width direction, and the first and second elastic wires 2, 3 are brought into a state where the first and second wires 2, 3 are deformed along the deformed nail with the first and second elastic wires 2, 3 being in a corrector mounting state where the first and second elastic wires 2, 3 are bound to each other by the binding means 4.


Patent
Maruho Hatsujyo Kogyo Co. and Maruho Co. | Date: 2013-08-30

A deformed nail corrector for correcting a deformed nail is provided that includes: a first elastic wire which has one end portion thereof fixed to one edge of the deformed nail in a width direction; a second elastic wire which has one end portion thereof fixed to the other edge of the deformed nail in the width direction; and a binding means which binds the first and second elastic wires to each other and is slidable along the first and second elastic wires in a bound state. The first and second elastic wires are brought into a state where the first and second wires are deformed along the deformed nail with the first and second, elastic wires being in a corrector mounting state where the first and second elastic wires are bound to each other by the binding means.


Patent
Maruho Co. | Date: 2015-01-14

The present invention aims to provide a cyclosporine external preparation showing improved transdermal absorbability of cyclosporine. The present invention provides an external preparation containing cyclosporine and a ketone.


Patent
Maruho Co. | Date: 2014-10-29

It is an object to provide a topical composition that is excellent in texture and feeling upon use. The present invention is a topical composition without water, satisfying the following: (A) the composition includes a silicone base in a proportion of 80% by weight or more; (B) the silicone base includes (b1) a silicone elastomer, (b2) a cyclic volatile methylsiloxane having 3 to 6 silicon atoms, and (b3) a linear dimethylpolysiloxane and/or linear methylphenylpolysiloxane; (C) the composition includes therein an active ingredient present in a dispersed or dissolved type; and (D) the composition does not contain any non-silicone thickener.


Patent
Maruho Co. | Date: 2013-05-29

The purpose is to provide a tacrolimus-containing pharmaceutical composition which is a creamy preparation for external application having good feeling upon use and has high stability of a main ingredient contained therein (high main ingredient residual ratio), and allows easy control of skin concentration of the main ingredient. The present invention relates to an oil-in-water type creamy composition comprising (A) tacrolimus, a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable solvate thereof, (B) an oil prepared by mixing (a) a medium-chain fatty acid triglyceride with (b) ethylene glycolsalicylate and/or diisopropylsebacate, (C) an emulsifying agent having a HLB value of 12 or more, and (D) a hydrophilic polymer, and having a pH value of 4 to 7.


Patent
Maruho Co. | Date: 2016-11-23

The present invention aims to provide a cyclosporine external preparation showing improved transdermal absorbability of cyclosporine. The present invention provides an external preparation containing cyclosporine and a ketone.


The present invention provides a dermal composition comprising a polymeric reversed micelle that allows a water-soluble drug to be efficiently encapsulated and that is superior in percutaneous absorptiveness and very safe, and provides a method that can produce the composition in simple steps. The dermal composition comprises a polymeric reversed micelle composed of an amphipathic polymer having a hydrophilic segment and a hydrophobic segment, wherein the polymeric reversed micelle has a configuration in which the hydrophilic segment is the core and the hydrophobic segment is the shell, and a water-soluble drug is encapsulated therein. The composition can be produced by blending an oil phase comprising the amphipathic polymer in an oily base agent with an aqueous phase comprising the water-soluble drug in an aqueous solvent, or by blending an oily base agent with an aqueous phase comprising the amphipathic polymer and the water-soluble drug in an aqueous solvent.

Loading Maruho Co. collaborators
Loading Maruho Co. collaborators